Patents by Inventor Julia Reid

Julia Reid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and materials for assessing homologous recombination deficiency
    Patent number: 12221656
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: February 11, 2025
    Assignee: Myriad Genetics, Inc.
    Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
  • Method of using biomarkers and clinical variables for predicting chemotherapy benefit
    Patent number: 12180551
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: December 31, 2024
    Assignee: MYRIAD INTERNATIONAL GMBH
    Inventors: Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
  • CANCER BIOMARKERS
    Publication number: 20240182979
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Application
    Filed: February 14, 2024
    Publication date: June 6, 2024
    Applicant: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
    Publication number: 20230117133
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 20, 2023
    Applicant: Myriad Genetics, Inc.
    Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
  • METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT
    Publication number: 20230116885
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 13, 2023
    Applicant: Myriad Genetics, Inc.
    Inventors: Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
  • Method of using biomarkers and clinical variables for predicting chemotherapy benefit
    Patent number: 11505832
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 22, 2022
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
  • GENE SIGNATURES FOR CANCER PROGNOSIS
    Publication number: 20220112565
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 14, 2022
    Applicant: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Julia Reid
  • Gene signatures for cancer prognosis
    Patent number: 11174517
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: November 16, 2021
    Assignee: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Julia Reid
  • GENE SIGNATURES FOR CANCER PROGNOSIS
    Publication number: 20210071269
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 11, 2021
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Gene signatures for cancer prognosis
    Patent number: 10876164
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 29, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT
    Publication number: 20200283855
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 10, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Alexander GUTIN, Julia REID, Ralf KRONENWETT, Marsel SCHEER
  • CANCER BIOMARKERS
    Publication number: 20200056246
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Steven STONE, Alexander GUTIN, Susanne WAGNER, Julia REID
  • Cancer Biomarkers
    Patent number: 10519513
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: December 31, 2019
    Assignee: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Cancer biomarkers
    Patent number: 10501807
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: December 10, 2019
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Methods and materials for assessing homologous recombination deficiency
    Patent number: 10400287
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 3, 2019
    Assignee: Myriad Genetics, Inc.
    Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
  • METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
    Publication number: 20190185939
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
  • CANCER BIOMARKERS
    Publication number: 20190153542
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 23, 2019
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • CANCER BIOMARKERS
    Publication number: 20180265930
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 20, 2018
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Cancer biomarkers
    Patent number: 9976188
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 22, 2018
    Assignee: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
    Publication number: 20170283879
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: February 15, 2017
    Publication date: October 5, 2017
    Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid